Induced pluripotent stem cells (iPSCs or iPS cells) are a form of pluripotent stem cells, generated directly from somatic (adult) cells. Pluripotent stem cells have significant potential in regenerative medicine. These possess the potential and capability to form various types of adult cells such as liver, heart, neurons, and pancreatic cells. These cells can proliferate indeterminately and can be used to repair or replace cells that are damaged due to diseases. In 2006, Shinya Yamanaka’s lab (Kyoto, Japan) for the first time successfully converted somatic (adult) cells into pluripotent stem cells. In 2012, Shinya Yamanaka along with Sir John Gurdon, was awarded the Nobel Prize for “the discovery of reprogramming mature cells to convert to pluripotent stem cells.” Embryonic stem cells are the most recognized type of pluripotent stem cells. The embryonic stem cells are generated by the destruction or manipulation of pre-implantation stage embryo. This led to much controversy and ethical issues regarding their use. Moreover, embryonic stem cells can be derived only from embryos, hence it has been infeasible to produce patient-matching embryonic stem cell lines. Induced pluripotent stem cells can be generated directly from adult tissues, bypassing the need for embryos and enabling the creation of a patient-matched pluripotent stem cell line for every individual.

The global induced pluripotent stem cells market is developing rapidly. The primary reason for inclination toward usage of induced pluripotent stem cells is their ability to make any cell or tissue required by the body to defend or combat diseases such as leukemia, spinal cord injury, heart disease, and diabetes. These cells can be modified or customized as per a patient’s genetic makeup, providing a perfect match. Additionally, induced pluripotent stem cells help in understanding human development at an early stage, thus offering an opportunity to develop rejection-proof, customized cells and tissues for efficacious transplantation. Increasing interest among scientists and researchers in this field and varied applications in disease treatment and other aspects is expected to drive the market. Furthermore, increased funding by governments and private sector and growing industry focus on induced pluripotent stem cells and related research, clinical applications, and awareness among the people about stem cells and induced pluripotent stem cells are likely to boost market growth during the forecast period. However, factors such as increasing costs associated with the treatment and reprogramming of cells, lengthy processes, and ethical issues hamper the growth of the market. Moreover, concerns such as low efficiency and proliferation rates, possible tumor risk, premature cell death, and incomplete programming are other factors that restrain the global induced pluripotent stem cell market.

The global induced pluripotent stem cells market can be segmented based on application, derived cell type, end-user, and region. In terms of application, the market can be divided into drug development, regenerative medicine, toxicity testing, and academic research. Based on derived cell type, the market can be segmented into fibroblasts, amniotic cells, hepatocytes, keratinocytes, and others. In terms of end-user, the market can be categorized into research organizations and hospitals.

Geographically, the induced pluripotent stem cells market can be segmented into five major regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global market, followed by Europe. Presence of definite business models in Canada and the U.S. contribute to the growth of the market in the region. Additionally, organizations are investing in research activities involving iPSCs. For example, the California Institute for Regenerative Medicine (CIRM) has encouraged research institutes to provide funds for the clinical focus on iPSC and their translation into clinical therapies. This is anticipated to contribute to the growth of the market in North America. The induced pluripotent stem cells market in countries in Asia Pacific is expected to witness rapid growth. Increasing number of research projects in countries such as Japan, Singapore, and Australia is anticipated to propel the market. Therefore, Asia Pacific and Latin America are projected to drive the global induced pluripotent stem cells market.

Key players in the global induced pluripotent stem cells market are Astellas Pharma Inc., Fate Therapeutics, FUJIFILM Holdings Corporation (Cellular Dynamics International, Inc.), EVOTEC, Japan Tissue Engineering Co., Ltd, ViaCyte, Inc., and Vericel Corporation, among others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Induced Pluripotent Stem Cells Market